Retour

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

Calendar Calendar of Events

WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in The Citizens JMP Life Sciences Conference on May 13, 2024.

GlobeNewswire Inc. • 09/05/2024 à 14:00:00
Aquestive Therapeutics, Inc. Common Stock
Address: 30 TECHNOLOGY DRIVE
Postal Code: 07059
City: WARREN
State: NJ
Phone Number: 908-941-1900
Website: https://www.aquestive.com
Status: Active
Company Info

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

List Date2018-07-25
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001398733
Composite figiBBG00L9HP0Z0
Share Class figiBBG00L9HP1R7
Market Cap283,129,835 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees135
Share Class Shares Outstanding91040000
Weighted Shares Outstanding91038532
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
3.145
3.265
3.235
3.195
3.265
Variance
-3.68%
1.24%
1.28%
-2.14%
5.29%
Open
3.265
3.225
3.194
3.265
3.101
Highest
3.315
3.305
3.328
3.27
3.315
Lowest
3.31
3.296
3.311
3.266
3.306
History
PeriodVarhighestlowest
1 week
0.29%
3.315
3.11
1 month
-24.73%
4.4
3.11
3 month
11.75%
2.895
2.6
6 month
77.71%
1.8
1.73
1 year
43.98%
2.455
1.2514
3 year
-10.68%
3.52
0.618
5 year
-38.66%
5.6
0.618
10 year
-79.34%
19.3
0.618
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-02 2023-08-07 2023-11-06 UNPUB
Assets 61,285,000 56,994,000 59,448,000 UNPUB
Current Assets 43,706,000 39,788,000 42,457,000 UNPUB
Current Liabilities 40,383,000 38,653,000 24,057,000 UNPUB
Equity -109,235,000 -106,651,000 -102,927,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent -109,235,000 -106,651,000 -102,927,000 UNPUB
Liabilities 170,520,000 163,645,000 162,375,000 UNPUB
Liabilities And Equity 61,285,000 56,994,000 59,448,000 UNPUB
Noncurrent Assets 17,579,000 17,206,000 16,991,000 UNPUB
Noncurrent Liabilities 130,137,000 124,992,000 138,318,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-02 2023-08-07 2023-11-06 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -391,000 -4,446,000 2,481,000 UNPUB
Net Cash Flow, Continuing -391,000 -4,446,000 2,481,000 UNPUB
Net Cash Flow From Financing Activities -9,205,000 4,287,000 4,979,000 UNPUB
Net Cash Flow From Financing Activities, Continuing -9,205,000 4,287,000 4,979,000 UNPUB
Net Cash Flow From Investing Activities -2,000 -826,000 -151,000 UNPUB
Net Cash Flow From Investing Activities, Continuing -2,000 -826,000 -151,000 UNPUB
Net Cash Flow From Operating Activities 8,816,000 -7,907,000 -2,347,000 UNPUB
Net Cash Flow From Operating Activities, Continuing 8,816,000 -7,907,000 -2,347,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-02 2023-08-07 2023-11-06 UNPUB
Comprehensive Income/Loss 8,068,000 -5,792,000 -2,035,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent 8,068,000 -5,792,000 -2,035,000 UNPUB
Other Comprehensive Income/Loss 8,068,000 -5,792,000 -2,035,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-02 2023-08-07 2023-11-06 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses 3,066,000 18,749,000 15,177,000 UNPUB
Cost Of Revenue 4,737,000 6,617,000 4,798,000 UNPUB
Costs And Expenses 15,739,000 17,450,000 15,379,000 UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit 6,397,000 6,624,000 8,204,000 UNPUB
Income/Loss From Continuing Operations After Tax 8,068,000 -5,792,000 -2,035,000 UNPUB
Income/Loss From Continuing Operations Before Tax 8,068,000 -5,508,000 -2,175,000 UNPUB
Income Tax Expense/Benefit 0 284,000 -140,000 UNPUB
Interest Expense, Operating 1,435,000 1,373,000 1,256,000 UNPUB
Net Income/Loss 8,068,000 -5,792,000 -2,035,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent 8,068,000 -5,792,000 -2,035,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic 8,068,000 -5,792,000 -2,035,000 UNPUB
Operating Expenses 11,002,000 10,833,000 10,581,000 UNPUB
Operating Income/Loss -4,605,000 -4,209,000 -2,377,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 11,134,000 13,241,000 13,002,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-04 2022-08-02 2022-11-01 2023-03-31
Assets 56,529,000 56,310,000 51,845,000 57,070,000
Current Assets 42,585,000 43,505,000 38,087,000 39,888,000
Current Liabilities 24,184,000 29,636,000 36,560,000 39,528,000
Equity -93,143,000 -96,357,000 -107,819,000 -118,554,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent -93,143,000 -96,357,000 -107,819,000 -118,554,000
Liabilities 149,672,000 152,667,000 159,664,000 175,624,000
Liabilities And Equity 56,529,000 56,310,000 51,845,000 57,070,000
Noncurrent Assets 13,944,000 12,805,000 13,758,000 17,182,000
Noncurrent Liabilities 0 0 123,104,000 136,096,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-04 2022-08-02 2022-11-01 2023-03-31
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -13,288,000 2,959,000 954,000 -751,000
Net Cash Flow, Continuing -13,288,000 2,959,000 954,000 -751,000
Net Cash Flow From Financing Activities 1,298,000 10,198,000 -138,000 11,562,000
Net Cash Flow From Financing Activities, Continuing 1,298,000 10,198,000 -138,000 11,562,000
Net Cash Flow From Investing Activities -104,000 -677,000 -1,717,000 -2,524,000
Net Cash Flow From Investing Activities, Continuing -104,000 -677,000 -1,717,000 -2,524,000
Net Cash Flow From Operating Activities -14,482,000 -6,562,000 2,809,000 -9,789,000
Net Cash Flow From Operating Activities, Continuing -14,482,000 -6,562,000 2,809,000 -9,789,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-04 2022-08-02 2022-11-01 2023-03-31
Comprehensive Income/Loss -13,220,000 -16,302,000 -12,536,000 -54,410,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -13,220,000 -16,302,000 -12,536,000 -54,410,000
Other Comprehensive Income/Loss 0 0 -12,536,000 -54,410,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-04 2022-08-02 2022-11-01 2023-03-31
Basic Earnings Per Share 0 0 0 -1
Benefits Costs and Expenses 25,490,000 29,567,000 23,999,000 102,090,000
Cost Of Revenue 4,214,000 5,242,000 4,625,000 UNPUB
Costs And Expenses 22,008,000 26,027,000 20,316,000 102,090,000
Diluted Earnings Per Share 0 0 0 -1
Gross Profit 8,056,000 8,023,000 6,838,000 UNPUB
Income/Loss From Continuing Operations After Tax -13,220,000 -16,302,000 -12,536,000 -54,410,000
Income/Loss From Continuing Operations Before Tax -13,220,000 -16,302,000 -12,536,000 -54,410,000
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating 1,618,000 1,635,000 1,649,000 6,552,000
Net Income/Loss -13,220,000 -16,302,000 -12,536,000 -54,410,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -13,220,000 -16,302,000 -12,536,000 -54,410,000
Net Income/Loss Available To Common Stockholders, Basic -13,220,000 -16,302,000 -12,536,000 -54,410,000
Operating Expenses 17,794,000 20,785,000 15,691,000 89,746,000
Operating Income/Loss -9,738,000 -12,762,000 -8,853,000 -42,066,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 12,270,000 13,265,000 11,463,000 47,680,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-04 2021-08-03 2021-11-02 2022-03-08
Assets 61,923,000 66,875,000 65,293,000 61,993,000
Current Assets 44,443,000 50,998,000 50,210,000 47,259,000
Current Liabilities 20,050,000 23,035,000 25,039,000 21,964,000
Equity -51,798,000 -53,769,000 -60,345,000 -82,134,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent -51,798,000 -53,769,000 -60,345,000 -82,134,000
Liabilities 113,721,000 120,644,000 125,638,000 144,127,000
Liabilities And Equity 61,923,000 66,875,000 65,293,000 61,993,000
Noncurrent Assets 17,480,000 15,877,000 15,083,000 14,734,000
Noncurrent Liabilities 0 0 100,599,000 122,163,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-04 2021-08-03 2021-11-02 2022-03-08
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -4,309,000 6,736,000 -3,070,000 -3,783,000
Net Cash Flow, Continuing -4,309,000 6,736,000 -3,070,000 -3,783,000
Net Cash Flow From Financing Activities 9,891,000 8,686,000 6,078,000 30,109,000
Net Cash Flow From Financing Activities, Continuing 9,891,000 8,686,000 6,078,000 30,109,000
Net Cash Flow From Investing Activities -103,000 -194,000 -83,000 -913,000
Net Cash Flow From Investing Activities, Continuing -103,000 -194,000 -83,000 -913,000
Net Cash Flow From Operating Activities -14,097,000 -1,756,000 -9,065,000 -32,979,000
Net Cash Flow From Operating Activities, Continuing -14,097,000 -1,756,000 -9,065,000 -32,979,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-04 2021-08-03 2021-11-02 2022-03-08
Comprehensive Income/Loss -14,672,000 -12,367,000 -14,555,000 -70,539,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -14,672,000 -12,367,000 -14,555,000 -70,539,000
Other Comprehensive Income/Loss 0 0 -14,555,000 -70,539,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-04 2021-08-03 2021-11-02 2022-03-08
Basic Earnings Per Share 0 0 0 -2
Benefits Costs and Expenses 25,794,000 27,712,000 27,842,000 121,371,000
Cost Of Revenue 2,757,000 4,466,000 4,400,000 UNPUB
Costs And Expenses 19,647,000 21,862,000 21,255,000 121,371,000
Diluted Earnings Per Share 0 0 0 -2
Gross Profit 8,365,000 10,879,000 8,887,000 UNPUB
Income/Loss From Continuing Operations After Tax -14,672,000 -12,367,000 -14,555,000 -70,539,000
Income/Loss From Continuing Operations Before Tax -14,672,000 -12,367,000 -14,555,000 -70,539,000
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating 2,761,000 2,757,000 2,787,000 10,049,000
Net Income/Loss -14,672,000 -12,367,000 -14,555,000 -70,539,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -14,672,000 -12,367,000 -14,555,000 -70,539,000
Net Income/Loss Available To Common Stockholders, Basic -14,672,000 -12,367,000 -14,555,000 -70,539,000
Operating Expenses 16,890,000 17,396,000 16,855,000 85,511,000
Operating Income/Loss -8,525,000 -6,517,000 -7,968,000 -34,679,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 11,122,000 15,345,000 13,287,000 50,832,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-05 2020-08-04 2020-11-04 2021-03-09
Assets 64,487,000 63,546,000 50,423,000 62,884,000
Current Assets 51,088,000 43,909,000 31,684,000 44,625,000
Current Liabilities 15,362,000 14,882,000 18,373,000 21,104,000
Equity -20,829,000 -21,388,000 -36,519,000 -48,497,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent -20,829,000 -21,388,000 -36,519,000 -48,497,000
Liabilities 85,316,000 84,934,000 86,942,000 111,381,000
Liabilities And Equity 64,487,000 63,546,000 50,423,000 62,884,000
Noncurrent Assets 13,399,000 19,637,000 18,739,000 18,259,000
Noncurrent Liabilities 0 0 68,569,000 90,277,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-05 2020-08-04 2020-11-04 2021-03-09
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -13,805,000 -10,099,000 -8,358,000 -17,519,000
Net Cash Flow, Continuing -13,805,000 -10,099,000 -8,358,000 -17,519,000
Net Cash Flow From Financing Activities -37,000 10,000 -7,000 28,457,000
Net Cash Flow From Financing Activities, Continuing -37,000 10,000 -7,000 28,457,000
Net Cash Flow From Investing Activities -131,000 -112,000 -38,000 -517,000
Net Cash Flow From Investing Activities, Continuing -131,000 -112,000 -38,000 -517,000
Net Cash Flow From Operating Activities -13,637,000 -9,997,000 -8,313,000 -45,459,000
Net Cash Flow From Operating Activities, Continuing -13,637,000 -9,997,000 -8,313,000 -45,459,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-05 2020-08-04 2020-11-04 2021-03-09
Comprehensive Income/Loss -16,530,000 -2,334,000 -16,551,000 -55,783,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -16,530,000 -2,334,000 -16,551,000 -55,783,000
Other Comprehensive Income/Loss 0 0 0 -55,783,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-05 2020-08-04 2020-11-04 2021-03-09
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses 22,626,000 21,280,000 22,041,000 101,632,000
Cost Of Revenue 3,659,000 3,539,000 2,978,000 12,964,000
Costs And Expenses 22,626,000 21,280,000 22,041,000 88,742,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit 5,106,000 18,136,000 5,282,000 32,885,000
Income/Loss From Continuing Operations After Tax -16,530,000 -2,334,000 -16,551,000 -55,783,000
Income/Loss From Continuing Operations Before Tax -16,530,000 -2,334,000 -16,551,000 -55,783,000
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating 2,771,000 2,747,000 2,778,000 11,064,000
Net Income/Loss -16,530,000 -2,334,000 -16,551,000 -55,783,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -16,530,000 -2,334,000 -16,551,000 -55,783,000
Net Income/Loss Available To Common Stockholders, Basic -16,530,000 -2,334,000 -16,551,000 -55,783,000
Operating Expenses 22,626,000 17,741,000 19,063,000 75,778,000
Operating Income/Loss -13,861,000 395,000 -13,781,000 -42,893,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 8,765,000 21,675,000 8,260,000 45,849,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-08 2019-08-06 2019-11-05 2020-03-11
Assets 67,979,000 50,408,000 48,818,000 78,479,000
Current Assets 55,958,000 39,064,000 38,060,000 68,314,000
Current Liabilities 29,638,000 24,629,000 20,053,000 18,555,000
Equity -6,056,000 -24,657,000 -34,459,000 -6,122,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent -6,056,000 -24,657,000 -34,459,000 -6,122,000
Liabilities 74,035,000 75,065,000 83,277,000 84,601,000
Liabilities And Equity 67,979,000 50,408,000 48,818,000 78,479,000
Noncurrent Assets 12,021,000 11,344,000 10,758,000 10,165,000
Noncurrent Liabilities 0 0 63,224,000 66,046,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-08 2019-08-06 2019-11-05 2020-03-11
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -20,665,000 -17,769,000 -1,251,000 -11,273,000
Net Cash Flow, Continuing -20,665,000 -17,769,000 -1,251,000 -11,273,000
Net Cash Flow From Financing Activities -2,609,000 -493,000 13,629,000 49,600,000
Net Cash Flow From Financing Activities, Continuing -2,609,000 -493,000 13,629,000 49,600,000
Net Cash Flow From Investing Activities -376,000 -110,000 -91,000 -663,000
Net Cash Flow From Investing Activities, Continuing -376,000 -110,000 -91,000 -663,000
Net Cash Flow From Operating Activities -17,680,000 -17,166,000 -14,789,000 -60,210,000
Net Cash Flow From Operating Activities, Continuing -17,680,000 -17,166,000 -14,789,000 -60,210,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-08 2019-08-06 2019-11-05 2020-03-11
Comprehensive Income/Loss -14,726,000 -20,472,000 -18,412,000 -66,246,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -14,726,000 -20,472,000 -18,412,000 -66,246,000
Other Comprehensive Income/Loss 0 0 0 -66,246,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-08 2019-08-06 2019-11-05 2020-03-11
Basic Earnings Per Share -1 -1 -1 UNPUB
Benefits Costs and Expenses 0 0 0 118,855,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 25,717,000 29,817,000 23,420,000 118,855,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -14,726,000 -20,472,000 -18,412,000 -66,246,000
Income/Loss From Continuing Operations Before Tax -14,726,000 -20,472,000 -18,412,000 -66,246,000
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating 1,926,000 1,937,000 2,652,000 9,318,000
Net Income/Loss -14,726,000 -20,472,000 -18,412,000 -66,246,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -14,726,000 -20,472,000 -18,412,000 -66,246,000
Net Income/Loss Available To Common Stockholders, Basic -14,726,000 -20,472,000 -18,412,000 -66,246,000
Operating Expenses 25,717,000 29,817,000 23,420,000 105,277,000
Operating Income/Loss -13,074,000 -18,688,000 -11,002,000 -52,668,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 12,643,000 11,129,000 12,418,000 52,609,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2018-11-06 2019-03-14
Assets UNPUB UNPUB 90,010,000 86,851,000
Current Assets UNPUB UNPUB 77,359,000 74,201,000
Current Liabilities UNPUB UNPUB 21,329,000 32,952,000
Equity UNPUB UNPUB 23,444,000 10,080,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Equity Attributable To Parent UNPUB UNPUB 23,444,000 10,080,000
Liabilities UNPUB UNPUB 66,566,000 76,771,000
Liabilities And Equity UNPUB UNPUB 90,010,000 86,851,000
Noncurrent Assets UNPUB UNPUB 12,651,000 12,650,000
Noncurrent Liabilities UNPUB UNPUB 45,237,000 43,819,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2018-11-06 2019-03-14
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB 53,344,000 43,220,000
Net Cash Flow, Continuing UNPUB UNPUB 53,344,000 43,220,000
Net Cash Flow From Financing Activities UNPUB UNPUB 65,267,000 58,035,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 65,267,000 58,035,000
Net Cash Flow From Investing Activities UNPUB UNPUB -448,000 -1,824,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -448,000 -1,824,000
Net Cash Flow From Operating Activities UNPUB UNPUB -11,475,000 -12,991,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -11,475,000 -12,991,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2018-11-06 2019-03-14
Comprehensive Income/Loss UNPUB UNPUB -15,038,000 -61,376,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -15,038,000 -61,376,000
Other Comprehensive Income/Loss UNPUB UNPUB 0 -61,376,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2018-11-06 2019-03-14
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB 0 128,806,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB 22,471,000 128,806,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -15,038,000 -61,376,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -15,038,000 -61,376,000
Income Tax Expense/Benefit UNPUB UNPUB 0 0
Interest Expense, Operating UNPUB UNPUB 1,933,000 7,711,000
Net Income/Loss UNPUB UNPUB -15,038,000 -61,376,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Net Income/Loss Attributable To Parent UNPUB UNPUB -15,038,000 -61,376,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -15,038,000 -61,376,000
Operating Expenses UNPUB UNPUB 22,471,000 116,364,000
Operating Income/Loss UNPUB UNPUB -9,204,000 -48,934,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 0 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 0 0
Revenues UNPUB UNPUB 13,267,000 67,430,000
Calendar
20 May 2024 (Time UTC) Actual Previous Consensus
★
10:30
United States
★★
09:00
United States
★★
09:00
United States
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-5400.000
-17800.000
★
15:30
United States
-66000.000
-60000.000
★
15:30
United States
59500.000
53700.000
★
15:30
United States
-116600.000
-135800.000
★★
15:30
United States
3200.000
4400.000
★
15:30
United States
203000.000
215400.000
★
15:30
United States
200.000
-31400.000
★
15:30
United States
61800.000
62600.000
★
15:30
United States
1300.000
1300.000
★
15:30
United States
-25300.000
-9700.000
★
15:30
United States
204500.000
199600.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:AQST240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:AQST240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:AQST240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:AQST240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:AQST240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:AQST240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:AQST240517P00010000 OPASPS Put American 100 10 BATO 2024-05-17
O:AQST240517P00005500 OPASPS Put American 100 5.5 BATO 2024-05-17
O:AQST240517P00004500 OPASPS Put American 100 4.5 BATO 2024-05-17
O:AQST240517P00004000 OPASPS Put American 100 4 BATO 2024-05-17
O:AQST240517P00003500 OPASPS Put American 100 3.5 BATO 2024-05-17
O:AQST240517P00003000 OPASPS Put American 100 3 BATO 2024-05-17
O:AQST240517P00002000 OPASPS Put American 100 2 BATO 2024-05-17
O:AQST240517P00001500 OPASPS Put American 100 1.5 BATO 2024-05-17
O:AQST240517P00001000 OPASPS Put American 100 1 BATO 2024-05-17
O:AQST240517P00000500 OPASPS Put American 100 0.5 BATO 2024-05-17
O:AQST240517C00010000 OCASPS Call American 100 10 BATO 2024-05-17
O:AQST240517C00005500 OCASPS Call American 100 5.5 BATO 2024-05-17
O:AQST240517C00004500 OCASPS Call American 100 4.5 BATO 2024-05-17
O:AQST240517C00004000 OCASPS Call American 100 4 BATO 2024-05-17
O:AQST240517C00003500 OCASPS Call American 100 3.5 BATO 2024-05-17
O:AQST240517C00003000 OCASPS Call American 100 3 BATO 2024-05-17
O:AQST240517C00002000 OCASPS Call American 100 2 BATO 2024-05-17
O:AQST240517C00001500 OCASPS Call American 100 1.5 BATO 2024-05-17
O:AQST240517C00001000 OCASPS Call American 100 1 BATO 2024-05-17
O:AQST240517C00000500 OCASPS Call American 100 0.5 BATO 2024-05-17
O:AQST240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:AQST240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:AQST240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:AQST240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:AQST240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:AQST240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:AQST240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:AQST240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:AQST240419P00005500 OPASPS Put American 100 5.5 BATO 2024-04-19
O:AQST240419P00004500 OPASPS Put American 100 4.5 BATO 2024-04-19
O:AQST240419P00004000 OPASPS Put American 100 4 BATO 2024-04-19
O:AQST240419P00003500 OPASPS Put American 100 3.5 BATO 2024-04-19
O:AQST240419P00003000 OPASPS Put American 100 3 BATO 2024-04-19
O:AQST240419P00002000 OPASPS Put American 100 2 BATO 2024-04-19
O:AQST240419P00001500 OPASPS Put American 100 1.5 BATO 2024-04-19
O:AQST240419P00001000 OPASPS Put American 100 1 BATO 2024-04-19
O:AQST240419P00000500 OPASPS Put American 100 0.5 BATO 2024-04-19
O:AQST240419C00005500 OCASPS Call American 100 5.5 BATO 2024-04-19
O:AQST240419C00004500 OCASPS Call American 100 4.5 BATO 2024-04-19
O:AQST240419C00004000 OCASPS Call American 100 4 BATO 2024-04-19
O:AQST240419C00003500 OCASPS Call American 100 3.5 BATO 2024-04-19
O:AQST240419C00003000 OCASPS Call American 100 3 BATO 2024-04-19
O:AQST240419C00002000 OCASPS Call American 100 2 BATO 2024-04-19
O:AQST240419C00001500 OCASPS Call American 100 1.5 BATO 2024-04-19
O:AQST240419C00001000 OCASPS Call American 100 1 BATO 2024-04-19
O:AQST240419C00000500 OCASPS Call American 100 0.5 BATO 2024-04-19
O:AQST240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:AQST240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:AQST240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:AQST240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:AQST240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:AQST240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:AQST240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:AQST240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:AQST240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:AQST240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:AQST240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:AQST240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:AQST240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:AQST240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:AQST240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:AQST240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:AQST240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:AQST240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:AQST240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:AQST240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:AQST231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:AQST231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:AQST231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:AQST231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:AQST231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:AQST231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:AQST231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:AQST231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:AQST231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:AQST231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:AQST231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:AQST231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:AQST231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:AQST231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:AQST231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:AQST231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:AQST231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:AQST231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:AQST230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:AQST230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:AQST230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:AQST230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:AQST230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:AQST230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:AQST230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:AQST230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:AQST230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:AQST230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:AQST230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:AQST230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Calendar Calendar of Events
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in The Citizens JMP Life Sciences Conference on May 13, 2024.
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.
GlobeNewswire Inc. • 1mo ago
News News
Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
Aquestive Therapeutics (AQST) concluded the recent trading session at $4.14, signifying a +0.24% move from its prior day's close.
Zacks Investment Research • 1mo ago
stocks Changes in company's own shares
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share. At closing, the aggregate gross proceeds of the offering to Aquestive, before deducting underwriting discounts and commissions and other offering expenses paid by Aquestive, were approximately $75.0 million.
GlobeNewswire Inc. • 1mo ago
Stocks Changes in company's own shares
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share. At closing, the aggregate gross proceeds of the offering to Aquestive, before deducting underwriting discounts and commissions and other offering expenses paid by Aquestive, were approximately $75.0 million.
GlobeNewswire Inc. • 1mo ago
stocks News
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $4.38, denoting no change from the preceding trading day.
Zacks Investment Research • 1mo ago
News News
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $4.38, denoting no change from the preceding trading day.
Zacks Investment Research • 1mo ago
Stocks Initial Public Offerings
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be approximately $75.0 million. The Company intends to use the net proceeds received from the offering, together with the Company’s existing cash and cash equivalents, primarily to advance the development and commercialization of its product pipeline, including Anaphylm™ (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, and Libervant™ (diazepam) Buccal Film for the treatment of seizure clusters in epilepsy patients aged two to five, and for working capital, capital expenditures and general corporate purposes. In addition, Aquestive has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are to be sold by the Company. The offering is expected to close on or about March 22, 2024, subject to satisfaction of customary closing conditions.
GlobeNewswire Inc. • 2mo ago
Stocks Changes in company's own shares
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. All of the securities in the public offering are being offered by Aquestive. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
GlobeNewswire Inc. • 2mo ago
News News
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks Investment Research • 2mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT